Prostate Cell News Volume 10.28 | Aug 2 2019

TOP STORY

The Androgen Receptor Regulates a Druggable Translational Regulon in Advanced Prostate Cancer

Researchers demonstrated that androgen receptor (AR) used translation machinery to shape the cellular proteome. They showed that AR was a negative regulator of protein synthesis and identified an unexpected relationship between AR and the process of translation initiation in vivo. [Sci Transl Med] Abstract

(Ranked by impact factor of the journal)

Loss of the Tumor Suppressor, Tp53, Enhances the Androgen Receptor-Mediated Oncogenic Transformation and Tumor Development in the Mouse Prostate

Scientists report a novel mouse model, in which elevated transgenic AR expression and Trp53 deletion occurred simultaneously in mouse prostatic epithelium to mimic human prostate cancer cells. [Oncogene] Abstract

Suppression of Prostate Cancer Pathogenesis Using an MDA-9/Syntenin (SDCBP) PDZ1 Small Molecule Inhibitor

PDZ1 domain-targeted small molecule blocked tumor cell invasion and migration in vitro, and metastasis in vivo. [Mol Cancer Ther] Abstract

EGF-Activated PI3K/Akt Signaling Coordinates Leucine Uptake by Regulating LAT3 Expression in Prostate Cancer

Inhibition of PI3K/Akt signaling significantly reduced leucine transport in LNCaP and PC-3 human prostate cancer cell lines, while growth factor addition significantly increased leucine uptake. [Cell Commun Signal] Full Article

Characterization of CD44 Intracellular Domain Interaction with RUNX2 in PC3 Human Prostate Cancer Cells

PC3 and PC3 cells overexpressing RUNX2 protein were analyzed for RUNX2/intracellular domain of CD44 interaction by immunoprecipitation, immunoblotting, and Immunofluorescence analyses. [Cell Commun Signal] Full Article

The STAT3 Inhibitor Galiellalactone Inhibits the Generation of MDSC‐Like Monocytes by Prostate Cancer Cells and Decreases Immunosuppressive and Tumorigenic Factors

Primary human monocytes were cocultured with prostate cancer cells or with conditioned medium from prostate cancer cells in the presence or absence of the STAT3 inhibitor galiellalactone. [Prostate] Full Article

Synthesis and Preclinical Evaluation of Radio-Iodinated GRPR/PSMA Bispecific Heterodimers for the Theranostics Application in Prostate Cancer

In vivo specificity for all heterodimers was studied in PC-3 and LNCaP xenografts. [¹²⁵I]I-BO530 was evaluated in PC-3pip xenografts. [Pharmaceutics] Full Article

The Effects of Cernitin^® on Inflammatory Parameters and Benign Prostatic Hyperplasia: An In Vitro Study

The authors investigated the cellular mechanisms by which Cernitin^® induced its effects on human prostatic cell lines BPH‐1 and WPMY‐1 and primary human peripheral blood mononuclear cells in vitro. [Phytother Res] Abstract

Transmembrane Channel-Like 5 (TMC5) Promotes Prostate Cancer Cell Proliferation through Cell Cycle Regulation

Scientists assessed the mRNA expression level of TMC5 in prostate cancer with the public databases Cancer Genome Atlas and Oncomine. The biological functions were demonstrated by bioinformatics methods and siRNA mediated knockdown experiments. [Biochimie] Abstract

Subscribe to one of our other 19 science newsletters such as Mammary Cell News & ESC & iPSC News.

Novel Treatment Options in the Management of Metastatic Castration-Naïve Prostate Cancer; Which Treatment Modality to Choose?

The authors summarize trial data to provide guidance for treatment selection in metastatic castration-naïve prostate cancer. [Ann Oncol] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

Anixa Biosciences Announces VA North Texas Health Care System to Join Cchek™ Prostate Cancer Study

Anixa Biosciences, Inc. announced that the VA North Texas Health Care System and its non-profit affiliate, the Dallas VA Research Corporation, have joined Anixa’s ongoing prostate cancer Cchek™ study. [Anixa Biosciences, Inc.] Press Release

US FDA Approves Darolutamide, a New Treatment for Men with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)

The FDA has granted approval to darolutamide, a non-steroidal androgen receptor inhibitor, under the brand name Nubeqa^®. [Orion Corporation] Press Release

GEMoaB Announces First Patient Dosed with the Affinity-Tailored T-Cell-Adaptor GEM3PSCA in a Phase I Study in PSCA-Positive Late-Stage Solid Tumors

GEMoaB GmbH announced the dosing of the first patient in a Phase I open-label, dose escalation study of GEM3PSCA, an affinity-tailored adapter for T-cells. [GEMoaB GmbH (PR Newswire Association LLC)] Press Release

Modra Pharmaceuticals Announces First Patients Treated in Phase IIb Metastatic Prostate Cancer Trial

Modra Pharmaceuticals B.V. announced the start of patient treatment in its Phase IIb clinical study evaluating the efficacy and tolerability of its lead candidate, ModraDoc006/r, in metastatic castration-resistant prostate cancer. [Modra Pharmaceuticals B.V. (Business Wire, Inc.)] Press Release

‘Tropical Trump’ Sparks Unprecedented Crisis for Brazilian Science

Since Bolsonaro took office in January, Brazil’s researchers have faced funding cuts and repeated attempts by the administration to roll back protections for the environment and Indigenous populations. [Nature News] Editorial

‘No One Is Immune’: Alaska’s Scientists Despair over Plan to Shrink State Universities

The University of Alaska’s governing board plans to consolidate campuses to cope with a 40% cut in state funding. [Nature News] Editorial

NEW From Stem Cell Biology to New Therapies
November 6-8, 2019
Toronto, Ontario, Canada

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Position – Prostate Cancer (Roswell Park Comprehensive Cancer Center)

Scientific Communications Coordinator (STEMCELL Technologies Inc.)

Postdoctoral Scientist – Prostate Oncobiology (Cancer Research UK)

Research Officer – Tumor Progression (Garvan Institute of Medical Research)

Postdoctoral Researcher – Genitourinary Cancers (Columbia University)

Senior Endowed Professorship – Cellular Principles & Evolution (Stony Brook University)

Research Scientist – Prostate Cancer Progression & Resistance (MD Anderson Cancer Center)

Endowed Chair Faculty – Prostate Cancer (Cleveland Clinic Lerner College of Medicine of Case Western Reserve University)

Postdoctoral Position – Prostate Biology (University of Washington)

Postdoctoral Scientist – Prostate Organoids (Rutgers Cancer Institute of New Jersey)

Research Lab Specialist – Tumor Microenvironment & Cell Behavior (University of Southern California)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.